The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
Abstract
Despite years of research and hundreds of reports on tumor markers in oncology, the number of markers that have emerged as clinically useful is pitifully small. Often, initially reported studies of a marker show great promise, but subsequent studies on the same or related markers yield inconsistent conclusions or stand in direct contradiction to the promising results. It is imperative that we attempt to understand the reasons that multiple studies of the same marker lead to differing conclusions. A variety of methodologic problems have been cited to explain these discrepancies. Unfortunately, many tumor marker studies have not been reported in a rigorous fashion, and published articles often lack sufficient information to allow adequate assessment of the quality of the study or the generalizability of study results. The development of guidelines for the reporting of tumor marker studies was a major recommendation of the National Cancer Institute-European Organisation for Research and Treatment of Cancer (NCI-EORTC) First International Meeting on Cancer Diagnostics in 2000. As for the successful CONSORT initiative for randomized trials and for the STARD statement for diagnostic studies, we suggest guidelines to provide relevant information about the study design, preplanned hypotheses, patient and specimen characteristics, assay methods, and statistical analysis methods. In addition, the guidelines suggest helpful presentations of data and important elements to include in discussions. The goal of these guidelines is to encourage transparent and complete reporting so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While making revisions, conscious efforts were made to harmonize our recommendations with other reporting guidelines, and where possible we chose the same or similar wording for items [37,39,41,45,46].”
From Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement (2015) · cites this paper as [37]
In the citing paper
“These items have been identified as important in several well-known guidelines for reporting of clinical research [4],[38]–[41].”
From Reporting and Methods in Clinical Prediction Research: A Systematic Review (2012) · cites this paper as [4]
In the citing paper
“Most guidelines, such as the STROBE guidelines for the reporting of observational studies or the REMARK guidelines for tumour marker prognostic studies, specifically advise investigators to report both unadjusted results (i.e., from univariable analysis, yielding the association of each candidate predictor with the outcome) and adjusted results (i.e., from a multivariable analysis) [4],[38],[63].”
From Reporting and Methods in Clinical Prediction Research: A Systematic Review (2012) · cites this paper as [4]
In the citing paper
“However, none of these guidelines are entirely appropriate for prediction model studies.”
From Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement (2015) · cites this paper as [37]
In the citing paper
“However, the focus of the REMARK checklist is primarily on prognostic factors and not prediction models, whereas the GRIPS statement is aimed at risk prediction using genetic risk factors and the specific methodological issues around handling large numbers of genetic variants.”
From Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement (2015) · cites this paper as [37]
Citations
Cites
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Self-citationMoher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gøtzsche, P. C., Lang, T., & for the CONSORT Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00012 · Cited by 3,835
Self-citationTowards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative.
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., de Vet, H. C. W., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00010 · Cited by 3,219
Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., & de Vet, H. C. W. (2003) · BMJ · doi:10.1136/bmj.326.7379.41 · Cited by 3,215
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Systematic Reviews in Health Care : Meta-Analysis in Context
Egger, M., Smith, G. D., & Altman, D. G. (2000) · Cited by 2,312
Self-citationDangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic Factors
Altman, D. G., Lausen, B., Sauerbrei, W., & Schumacher, M. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.11.829 · Cited by 1,143
Self-citationThe Risk of Determining Risk with Multivariable Models
Concato, J., Feinstein, A. R., & Holford, T. R. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-3-199302010-00009 · Cited by 1,129
Cited by
Sorted by citations
Items 401–500 of 1,003
Luime, J. J., Colin, E. M., Hazes, J. M. W., & Lubberts, E. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.103283 · Cited by 87
Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response
Wennemers, M., Bussink, J., Scheijen, B., Nagtegaal, I. D., van Laarhoven, H. W. M., Raleigh, J. A., Varia, M. A., Heuvel, J. J. T. M., Rouschop, K. M. A., Sweep, F. C. G. J., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2934 · Cited by 92
Lundgren, K., Brown, M., Pineda, S., Cuzick, J. M., Salter, J., Zabaglo, L. A., Howell, A., Dowsett, M., Landberg, G., & the TransATAC investigators (2012) · Breast Cancer Research · doi:10.1186/bcr3161 · Cited by 87
van Nes, J. G. H., de Kruijf, E. M., Putter, H., Faratian, D., Munro, A. F., Campbell, F., Smit, V. T. H. B. M., Liefers, G., Kuppen, P. J. K., van de Velde, C. J. �., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1684-y · Cited by 88
Dalela, D., Santiago‐Jiménez, M., Yousefi, K., Karnes, R. J., Ross, A. E., Den, R. B., Freedland, S. J., Schaeffer, E. M., Dicker, A. P., Menon, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.9918 · Cited by 86
Grisanti, S., Almici, C., Consoli, F., Buglione, M., Verardi, R., Villaret, A. B., Bianchetti, A., Ciccarese, C., Mangoni, M., Ferrari, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103918 · Cited by 86
Baccelli, I., Stenzinger, A., Vogel, V., Pfitzner, B. M., Klein, C., Wallwiener, M., Scharpff, M., Saini, M., Holland‐Letz, T., Sinn, H., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2385 · Cited by 86
Lin, D. W., Newcomb, L. F., Brown, M. D., Sjoberg, D. D., Dong, Y., Brooks, J. D., Carroll, P. R., Cooperberg, M. R., Dash, A., Ellis, W. J., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.11.017 · Cited by 85
Zhang, Q., Huang, H., Liu, A., Jiang, L., Liu, C., Sun, B., Chen, L., Gao, Y., Xu, D., & Su, C. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.032 · Cited by 85
Joosse, S. A., Müller, V., Steinbach, B., Pantel, K., & Schwarzenbach, H. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.360 · Cited by 84
Epigenetic biomarkers in skin cancer
Greenberg, E. S., Chong, K. K., Huynh, K. T., Tanaka, R., & Hoon, D. S. �. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.020 · Cited by 85
Developing proteomic biomarkers for bladder cancer: towards clinical application
Frantzi, M., Latosinska, A., Flühe, L., Hupe, M. C., Critselis, E., Kramer, M. W., Merseburger, A. S., Mischak, H., & Vlahou, A. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.100 · Cited by 83
Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer
Ali, H. R., Dawson, S.-J., Blows, F. M., Provenzano, E., Pd, P., & Caldas, C. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.167 · Cited by 86
Loi, S., Michiels, S., Baselga, J. M., Bartlett, J. M. S., Singhal, S. K., Sabine, V. S., Sims, A. H., Sahmoud, T., Dixon, J. M., Piccart, M. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053292 · Cited by 85
Jayawardana, K. S., Schramm, S., Tembe, V., Mueller, S., Thompson, J. F., Scolyer, R. A., Mann, G. J., & Yang, J. Y. H. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.355 · Cited by 84
Casadevall, D., Clavé, S., Taus, Á., Hardy-Werbin, M., Rocha, P., Lorenzo, M., Menéndez, S., Salido, M., Albanell, J., Pijuán, L., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.04.014 · Cited by 84
Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer
Horeweg, N., de Bruyn, M., Nout, R. A., Stelloo, E., Kedzierska, K., León‐Castillo, A., Plat, A., Mertz, K. D., Osse, M., Jurgenliemk-Schulz, I. M., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0149 · Cited by 82
Ono, S., Oyama, T., Lam, S., Chong, K. K., Foshag, L. J., & Hoon, D. S. �. (2015) · Oncotarget · doi:10.18632/oncotarget.3142 · Cited by 83
Siggelkow, W., Boehm, D. U., Gebhard, S., Battista, M. J., Sicking, I., Lebrecht, A., Solbach, C., Hellwig, B., Rahnenführer, J., Koelbl, H., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-562 · Cited by 83
HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer
Lang, J. E., Mosalpuria, K., Cristofanilli, M., Krishnamurthy, S., Reuben, J. M., Singh, B., Bedrosian, I., Meric‐Bernstam, F., & Lucci, A. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9951-2 · Cited by 83
Feldt, M., Bjarnadottir, O., Kimbung, S., Jirström, K., Bendahl, P., Veerla, S., Grabau, D. A., Hedenfalk, I. A., & Borgquist, S. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0486-0 · Cited by 83
Individual participant data meta-analysis of prognostic factor studies: state of the art?
Abo-Zaid, G., Sauerbrei, W., & Riley, R. D. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-56 · Cited by 83
Self-citationCarlsson, A., Wingren, C., Kristensson, M., Rose, C., Fernö, M., Olsson, H. L., Jernström, H., Ek, S., Gustavsson, E., Ingvar, C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103125108 · Cited by 83
Abdel-Fatah, T. M. A., Middleton, F. K., Arora, A., Agarwal, D., Chen, T., Moseley, P. M., Perry, C., Doherty, R. E., Chan, S. Y. T., Green, A. R., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.10.013 · Cited by 86
Tewari, N., Zaitoun, A. M., Arora, A., Madhusudan, S., Ilyas, M., & Lobo, D. N. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-436 · Cited by 83
Paoletti, C., Li, Y., Muñiz, M. C., Kidwell, K., Aung, K., Thomas, D. G., Brown, M. E., Abramson, V. G., Irvin, W., Lin, N., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2781 · Cited by 83
Mirnezami, R., Jiménez, B., Li, J. V., Kinross, J. K., Veselkov, K., Goldin, R. D., Holmes, E. C., Nicholson, J. K., & Darzi, A. W. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31829d5c45 · Cited by 81
PBX3 Is Part of an EMT Regulatory Network and Indicates Poor Outcome in Colorectal Cancer
Lamprecht, S., Kaller, M., Schmidt, E. M., Blaj, C., Schiergens, T. S., Engel, J., Jung, A., Hermeking, H., Grünewald, T. G. P., Kirchner, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2572 · Cited by 81
Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas
Arnold, A., Daum, S., von Winterfeld, M., Berg, E., Hummel, M., Rau, B., Stein, U., & Treese, C. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02380-0 · Cited by 81
Filipits, M., Haddad, V., Schmid, K., Huynh, A. T., Dunant, A., André, F., Brambilla, E. M., Stahel, R. A., Pignon, J., Soria, J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2446 · Cited by 81
Elias, D., Vever, H., Lænkholm, A., Gjerstorff, M. F., Yde, C. W., Lykkesfeldt, A. E., & Ditzel, H. J. (2014) · Oncogene · doi:10.1038/onc.2014.138 · Cited by 83
Kadota, K., Yeh, Y., Villena‐Vargas, J., Cherkassky, L., Drill, E. N., Sima, C. S., Jones, D. R., Travis, W. D., & Adusumilli, P. S. (2015) · CHEST Journal · doi:10.1378/chest.14-3005 · Cited by 81
Schürch, C. M., Roelli, M. A., Forster, S., Wasmer, M.-H., Bruehl, F. K., Maire, R., Pancrazio, S. D., Ruepp, M., Giger, R., Perren, A. A., et al. (2019) · Thyroid · doi:10.1089/thy.2018.0555 · Cited by 81
Integrating molecular nuclear imaging in clinical research to improve anticancer therapy
de Vries, E. G. E., de Ruijter, L. K., Hooge, M. N. L., Dierckx, R. A. J. O., Elias, S. G., & Oosting, S. F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0123-y · Cited by 82
Fernández-Martínez, A., Pascual, T., Singh, B., Nuciforo, P. G., Rashid, N. U., Ballman, K. V., Campbell, J. D., Hoadley, K. A., Spears, P. A., Paré, L., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.6288 · Cited by 80
Gallo, V., Egger, M., McCormack, V., Farmer, P. B., Ioannidis, J. P. A., Kirsch‐Volders, M., Matullo, G., Phillips, D. H., Schoket, B., Strömberg, U., et al. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02561.x · Cited by 79
Jiang, Z., Chu, P. G., Woda, B. A., Liu, Q., Balaji, K. C., Rock, K. L., & Wu, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0504 · Cited by 79
Kimbung, S., Lettiero, B., Feldt, M., Bosch, A., & Borgquist, S. (2016) · Oncotarget · doi:10.18632/oncotarget.10746 · Cited by 79
Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer
Zlobec, I., Terracciano, L., Tornillo, L., Günthert, U., Vuong, T., Jass, J. R., & Lugli, A. (2008) · Gut · doi:10.1136/gut.2007.141192 · Cited by 79
Expression of the ribonucleases Drosha, Dicer, and Ago2 in colorectal carcinomas
Papachristou, D. J., Korpetinou, A., Giannopoulou, E., Antonacopoulou, A. G., Papadaki, H. H., Grivas, P. D., Scopa, C. D., & Kalofonos, H. P. (2011) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-011-1119-5 · Cited by 79
Biobanking Comes of Age: The Transition to Biospecimen Science
Vaught, J. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103246 · Cited by 78
Hypoxic regulation and prognostic value of LAMP3 expression in breast cancer
Nagelkerke, A., Mujčić, H., Bussink, J., Wouters, B. G., van Laarhoven, H. W. M., Sweep, F. C. G. J., & Span, P. N. (2011) · Cancer · doi:10.1002/cncr.25938 · Cited by 78
What is the clinical value of cancer stem cell markers in gliomas?
Dahlrot, R. H., Hermansen, S. K., Hansen, S., & Kristensen, B. W. (2013) · Europe PMC (PubMed Central) · Cited by 78
Perisanidis, C., Perisanidis, B., Wrba, F., Brandstetter, A., Gazzar, S. E., Papadogeorgakis, N., Seemann, R., Ewers, R., Kyzas, P., & Filipits, M. (2011) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2011.01071.x · Cited by 78
The Omics of Triple-Negative Breast Cancers
Xu, H., Eirew, P. D., Mullaly, S. C., & Aparicio, S. A. J. R. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.207167 · Cited by 80
Fountzilas, G., Valavanis, C., Kotoula, V., Eleftheraki, A. G., Kalogeras, K. T., Tzaida, O., Batistatou, A. K., Kronenwett, R., Wirtz, R. M., Bobos, M., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-10 · Cited by 78
Pichler, M., Stiegelbauer, V., Vychytilova‐Faltejskova, P., Ivan, C., Ling, H. Y., Winter, E., Zhang, X., Goblirsch, M. J., Wulf-Goldenberg, A., Ohtsuka, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0497 · Cited by 78
Zhang, Z., Zhang, L., Yu, G., Sun, Z., Wang, T., Tian, X., Duan, X., & Zhang, C. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04168-z · Cited by 78
Polymorphisms inXRCC1,XRCC3, andCCND1and Survival After Treatment for Metastatic Breast Cancer
Bewick, M. A., Conlon, M., & Lafrenie, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9923 · Cited by 78
Zhu, K., Dai, Z., & Zhou, J. (2013) · Biomarker Research · doi:10.1186/2050-7771-1-10 · Cited by 78
Funakoshi, T., Lee, C., & Hsieh, J. J.-D. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.11.008 · Cited by 78
Identification of Clinically Useful Cancer Prognostic Factors: What Are We Missing?
McShane, L. M., Altman, D. G., & Sauerbrei, W. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji193 · Cited by 78
Self-citationKim, D. J., Cho, E. J., Yu, K., Jang, I., Yoon, J., Park, T., & Cho, J. (2019) · Cancers · doi:10.3390/cancers11101497 · Cited by 78
Rai, B. P., Escrig, J. L. D., Vale, L., Kuusk, T., Čapoun, O., Soukup, V., Bruins, H. M., Yuan, Y., Violette, P. D., Santesso, N. A., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.03.027 · Cited by 77
EFNS guidelines on disease‐specific CSF investigations
Deisenhammer, F., Egg, R., Giovannoni, G., Hemmer, B., Petzold, A., Sellebjerg, F. T., Teunissen, C. E., & Tumani, H. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02595.x · Cited by 79
Briasoulis, E. C., Aravantinos, G., Kouvatseas, G., Pappas, P., Biziota, E., Sainis, I., Makatsoris, T., Varthalitis, I. I., Xanthakis, I., Vassias, A., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-263 · Cited by 76
Kashyap, A. S., Fernandez-Rodriguez, L., Zhao, Y., Monaco, G., Trefny, M. P., Yoshida, N., Martin, K., Sharma, A., Olieric, N., Shah, P., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.057 · Cited by 76
Zeng, X., Shi, G., He, Q., & Zhu, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-00268-9 · Cited by 78
Prognostic Determinants in Prostate Cancer
Martin, N. E., Mucci, L. A., Loda, M. F., & DePinho, R. A. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823b042c · Cited by 75
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib
Daemen, A., Wolf, D. M., Korkola, J. E., Griffith, O. L., Frankum, J. R., Brough, R., Jakkula, L. R., Wang, N. J., Natrajan, R., Reis-Filho, J. S., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2188-0 · Cited by 78
Banys-Paluchowski, M. J., Solomayer, E., Gebauer, G., Janni, W., Krawczyk, N., Lueck, H.-J., Becker, S., Huober, J., Kraemer, B., Wackwitz, B., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-480 · Cited by 76
Court, C. M., Hou, S., Winograd, P., Segel, N. H., Li, Q. W., Zhu, Y., Sadeghi, S., Finn, R. S., Ganapathy, E., Song, M., et al. (2018) · Liver Transplantation · doi:10.1002/lt.25062 · Cited by 76
Domingo, E., Camps, C., Kaisaki, P. J., Parsons, M. J., Mouradov, D., Pentony, M. M., Makino, S., Palmieri, M., Ward, R. L., Hawkins, N. J., et al. (2018) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(18)30117-1 · Cited by 80
SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma
Jin, G., Yu, W., Dong, H. F., Zhou, W., Gu, Y., Yu, H., Yu, H., Lü, X., Xian, Z., Liu, Y., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.028 · Cited by 75
Prognostic Impact of Autophagy Biomarkers for Cutaneous Melanoma
Tang, D. Y. L., Ellis, R. A., & Lovat, P. E. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00236 · Cited by 71
A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER‐positive breast cancer
Ali, H. R., Dawson, S., Blows, F., Provenzano, E., Leung, S., Nielsen, T., Pharoah, P., & Caldas, C. (2012) · Journal of Pathology · doi:10.1002/path.2976 · Cited by 80
Utility of Serum Procalcitonin for Screening and Risk Stratification of Medullary Thyroid Cancer
Machens, A., Lorenz, K., & Dralle, H. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1278 · Cited by 74
Smits, K. M., Schouten, L. J., van Dijk, B. A. C., de Kaa, C. A. H., Wouters, K. A. D., Oosterwijk, E., van Engeland, M., & van den Brandt, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1753 · Cited by 73
Jagdev, S., Gregory, W. M., Vasudev, N. S., Harnden, P., Sim, S., Thompson, D., Cartledge, J. J., Selby, P. J., & Banks, R. E. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605973 · Cited by 73
Gene Signatures in the Management of Hepatocellular Carcinoma
Hoshida, Y., Moeini, A., Alsinet, C., Kojima, K., & Villanueva, A. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.05.003 · Cited by 74
Predicting the outcome of chemotherapy for lung cancer
Rosell, R., Cecere, F. L., Santarpía, M., Reguart, N., & Tarón, M. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.01.011 · Cited by 73
TGFBI expression is associated with a better response to chemotherapy in NSCLC
Irigoyen, M., Pajares, M. J., Agorreta, J., Ponz‐Sarvisé, M., Salvo, E., Lozano, M. D., Pı́o, R., Bazo, I. G., & Rouzaut, A. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-130 · Cited by 73
Bachet, J., Maréchal, R., Demetter, P., Bonnetain, F., Couvelard, A., Svrcek, M., Bardier–Dupas, A., Hammel, P. R., Sauvanet, A., Louvet, C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr617 · Cited by 73
Caporarello, N., Lupo, G., Olivieri, M., Cristaldi, M., Cambria, M. T., Salmeri, M., & Anfuso, C. D. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7179 · Cited by 77
Radiomics and radiogenomics of primary liver cancers
Jeong, W. K., Jamshidi, N., Felker, E. R., Raman, S. S., & Lu, D. (2018) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2018.1007 · Cited by 72
Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis
Ku, J. H., Kang, M., Kim, H. S., Jeong, C. W., Kwak, C., & Kim, H. H. (2015) · BMC Cancer · doi:10.1186/s12885-015-1448-x · Cited by 72
Collinson, F. J., Hutchinson, M., Craven, R. A., Cairns, D. A., Zougman, A., Wind, T. C., Gahir, N., Messenger, M. P., Jackson, S., Thompson, D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0489 · Cited by 73
What can molecular pathology contribute to the management of renal cell carcinoma?
Stewart, G. D., O’Mahony, F. C., Powles, T. B., Riddick, A. C. P., Harrison, D. J., & Faratian, D. (2011) · Nature Reviews Urology · doi:10.1038/nrurol.2011.43 · Cited by 71
Koutras, A. K., Antonacopoulou, A. G., Eleftheraki, A. G., Dimitrakopoulos, F.-I. D., Koumarianou, A. A., Varthalitis, I. I., Fostira, F., Sgouros, J., Briasoulis, E. C., Bournakis, E., et al. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2011.37 · Cited by 72
Waidmann, O., Köberle, V., Bettinger, D., Trojan, J., Zeuzem, S., Schultheiß, M., Kronenberger, B., & Piiper, A. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.06.008 · Cited by 72
Tao, Y., Huang, J.-L., Zeng, S., Zhang, S., Fan, X., Wang, Z., Yang, H., Yuan, X., Wang, P., Wu, F., et al. (2013) · Hepatology · doi:10.1002/hep.26268 · Cited by 72
Tissue microarrays: emerging standard for biomarker validation
Hassan, S. N., Ferrario, C., Mamo, A., & Basik, M. (2008) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.10.009 · Cited by 72
Urinary Protein Biomarker Panel for the Detection of Recurrent Bladder Cancer
Rosser, C. J., Chang, M. N., Dai, Y. E., Ross, S., Mengual, L., Alcaraz, A., & Steve Goodison, B. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0035 · Cited by 72
Derr, R. S., van Hoesel, A. Q., Benard, A., Goossens-Beumer, I. J., Sajet, A., Dekker-Ensink, N. G., de Kruijf, E. M., Bastiaannet, E., Smit, V. T. H. B. M., van de Velde, C. J., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-604 · Cited by 71
Longitudinal Cytokine Expression during IMRT for Prostate Cancer and Acute Treatment Toxicity
Christensen, E. N., Pintilie, M., Evans, K., Lenarduzzi, M., Ménard, C. M., Catton, C., Diamandis, E. P., & Bristow, R. G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0245 · Cited by 72
Zlobec, I., Baker, K., Minoo, P., Jass, J. R., Terracciano, L., & Lugli, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1380 · Cited by 72
Gene Expression Profiling of Breast Cancer Brain Metastasis
Lee, J. Y., Park, K., Lee, E., Ahn, T., Jung, H. H., Lim, S. H., Hong, M. E., Do, I., Cho, E. Y., Kim, D., et al. (2016) · Scientific Reports · doi:10.1038/srep28623 · Cited by 74
Kim, H. S., Kim, M., Jeong, C. W., Kwak, C. H., Kim, H. H., & Ku, J. H. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.05.008 · Cited by 71
Proliferating CD8+ T Cell Infiltrates Are Associated with Improved Survival in Glioblastoma
Mauldin, I. S., Jo, J., Wages, N. A., Yogendran, L. V., Mahmutovic, A., Young, S. J., Lopes, M. B. S., Slingluff, C. L., Erickson, L. D., & Fadul, C. E. (2021) · Cells · doi:10.3390/cells10123378 · Cited by 74
Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes
Bradbury, P. A., Kulke, M. H., Heist, R. S., Zhou, W., Ma, C., Xu, W., Marshall, A. L., Zhai, R., Hooshmand, S. M., Asomaning, K., et al. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32832f3010 · Cited by 71
Goebel, G., Berger, R., Strasak, A. M., Egle, D., Müller‐Holzner, E., Schmidt, S. U., Rainer, J., Presul, E., Parson, W., Lang, S., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.510 · Cited by 71
Quantitative Measurement of Melanoma Spread in Sentinel Lymph Nodes and Survival
Ulmer, A., Dietz, K., Hodak, I., Polzer, B., Scheitler, S., Yıldız, M., Czyż, Z. T., Lehnert, P., Fehm, T. N., Hafner, C. M., et al. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001604 · Cited by 75
Calpain system protein expression in basal-like and triple-negative invasive breast cancer
Storr, S. J., Lee, K. W., Woolston, C. M., Safuan, S., Green, A. R., Macmillan, R. D., Benhasouna, A., Parr, T., Ellis, I. O., & Martin, S. G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds176 · Cited by 71
Sun, C., Xu, J., Song, J., Liu, C., Wang, J., Weng, C., Sun, H., Wei, H., Xiao, W., Sun, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5801 · Cited by 71
RORα and RORγ expression inversely correlates with human melanoma progression
Brożyna, A. A., Jóźwicki, W., Skobowiat, C., Jetten, A. M., & Slominski, A. T. (2016) · Oncotarget · doi:10.18632/oncotarget.11211 · Cited by 70
Soluble stroma‐related biomarkers of pancreatic cancer
Resovi, A., Bani, M. R., Porcu, L., Anastasia, A., Minoli, L., Allavena, P., Cappello, P., Novelli, F., Scarpa, A., Morandi, E., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708741 · Cited by 74
Riley, R. D., Ridley, G. F., Williams, K. J., Altman, D. G., Hayden, J. A., & de Vet, H. C. W. (2007) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.02.004 · Cited by 71
Self-citationCriteria for Scientific Evaluation of Novel Markers: A Perspective
Moons, K. G. M. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.134155 · Cited by 70
Naidoo, K., Wai, P. T., Maguire, S. L., Daley, F. M., Haider, S. A., Kriplani, D., Campbell, J., Mirza, H., Grigoriadis, A. E., Tutt, A. N. J., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0760 · Cited by 72
Quintanal-Villalonga, À., Molina‐Pinelo, S., Cirauqui, C., Ojeda-Márquez, L., Marrugal, Á., Suárez, R. A., Conde, E., Ponce-Aix, S., Enguita, A. B., Carnero, A., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.021 · Cited by 70
Metadata
- Authors
- McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- McShane, Lisa M.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-08-17
- Volume
- 97
- Issue
- 16
- Pages
- 1180-1184
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2096910745
- Cited by
- 2,162
- References
- 46
- Citations by year
- 2026: 112 · 2025: 38 · 2024: 44 · 2023: 42 · 2022: 39 · 2021: 93 · 2020: 100 · 2019: 126 · 2018: 116 · 2017: 127 · 2016: 163 · 2015: 192 · 2014: 167 · 2013: 150 · 2012: 173
- FWCI
- 56.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Yale University
- Yale Cancer Center
- Cancer Research UK
- Translational Cancer Research Network
- National Cancer Institute (MD 20892, 20892)
- Topics
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
- Health Sciences › Medicine › Oncology › Cancer Diagnosis and Treatment
- Keywords
- tumor markers, prognostic factors, reporting guidelines, remarks, reporting quality, methodological discrepancies, research design, assay method, statistical analysis methods, cancer diagnosis, research transparency
- MeSH terms
- Humans, Neoplasms, Research Design, Biomarkers, Tumor, Information Dissemination, Biomedical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
